The Psychedelic Drugs market report includes the key vital advancements of the market involving new item dispatch, explore and improvement, associations, acquisitions and mergers, coordinated efforts and joint endeavors understandings, and territorial development of fundamental players in the market on the worldwide premise. The study incorporates point by point data of maker’s plans of action, systems, income development and every one of the information required that would profit the individual directing the market research. The report gives the exhaustive organization profiles of some of the noteworthy market players, which will remain dynamic in fated decades.
Global Psychedelic drugs market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Growing prevalence of depression worldwide and increase in special designation from the regulatory authorities to the company to expedite the development process are the key factors for market growth.
Psychedelic drugs are also known as psychedelics are the class of hallucinogenic drugs including both classic hallucinogens as well as dissociative drugs that are used recreationally, to alter and enhance the sensory perception, elevate the mood swings, thought process, energy level promoting spiritual experiences. Psychedelic drugs have been used experimentally for psychological treatment and are able to control mind hence maintaining peace.
According to the statistic published in our World in Data 2017, the global burden of mental and substance use disorders were 122.76 million. Increase cases of mental disorders and accelerating demand of novel therapies are the drivers promoting the growth of this market.
Key Market Players: COMPASS, The Emmes Company, LLC, Klarisana, AstraZeneca, F. Hoffmann-La Roche Ltd, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Pfizer Inc, Mylan N.V. , Merck & Co., Inc, Alkermes, ALLERGAN, H. Lundbeck A/S among others.
REQUEST FOR SAMPLE PDF OF REPORT @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-psychedelic-drugs-market
Market Drivers
- Increase in the prevalence of depression worldwide can act as a driver for the growth of this market
- Treatment for psychedelic drugs dependency can also boost the market growth
- Changing life style and requirement for enhanced and better life quality is propelling the market growth
- Increase special designation from the regulatory authority can drive the market growth
Segmentation: Global Psychedelic Drugs Market
By Application
- Major Depressive Disorder
- Resistant depression
- Panic disorder
- Post-traumatic stress disorder
- Opiate Addiction
- Others
By Drugs
- Lysergic Acid Diethylamide (LSD)
- 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
- Phencyclidine
- Gamma Hydroxybutyric Acid (GHB)
- Ketamine
- Ayahuasca
- Salvia
- Psilocybin
- Others
By Route of Administration
- Oral
- Injectable
- Inhalation
By Distribution Channel
- Direct Retailers
- Online Pharmacies
- Others
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Geography
- North America
- South America
- Europe
- Asia-Pacific
DOWNLOAD PDF COPY OF TABLE OF CONTENT @ https://databridgemarketresearch.com/toc/?dbmr=global-psychedelic-drugs-market
Key Developments in the Market:
- In October 2018, COMPASS received Breakthrough Therapy designation from the FDA for psilocybin therapy for the treatment of resistant depression. With Breakthrough Therapy designation, company can obtain all fast track designation features and FDA commitment and guidance ensuring efficient drug development programme
- In August 2018, COMPASS received new drug application approval from the FDA for the psilocybin therapy for the treatment of resistant depression. If the trial is successful, it will change the treatment landscape of patients suffering from resistant depression
Competitive Analysis:
Global psychedelic drugs market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global psychedelic drugs market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
INQUIRE | FOR MORE INFORMATION ON THIS REPORT @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-psychedelic-drugs-market
The Psychedelic Drugs report provides a detailed analysis on current and future market trends to identify the investment opportunities. This report also provides market forecast till 2026, using estimated market values as the base numbers. Key market trends across the business segments, regions and countries are also mentioned in the report. Key developments and strategies observed in the market, in depth company profiles of key players and upcoming prominent players are also encompassed in the report. This Psychedelic Drugs report features market opportunities and recommendations for new investments.
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Sopan Gedam
Data Bridge Market Research
Tel: +1-888-387-2818